Form 4: Director Behbahani Boosts BDTX Stake

Black Diamond Therapeutics director Ali Behbahani acquired 6,919 shares of common stock at $2.15 per share, opting for equity in lieu of cash compensation.

Summary

• Ali Behbahani, a Director and 10% Owner of Black Diamond Therapeutics, Inc. (BDTX), acquired 6,919 shares of common stock.
• The transaction occurred on March 20, 2026, with a price of $2.15 per share, based on the closing market price on March 19, 2026.
• These shares were issued as equity compensation for annual services as a non-employee director, in accordance with the company's Fifth Amended and Restated Non-Employee Director Compensation Policy.
• Following this transaction, Behbahani directly owns 93,568 shares and indirectly owns 4,448,757 shares through New Enterprise Associates 16, L.P.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's choice to receive equity over cash compensation typically indicates confidence in the company's future performance and aligns their interests with shareholders.

Positives

• A director choosing to receive equity instead of cash compensation can signal confidence in the company's future prospects.
• The increase in direct beneficial ownership by a director aligns their interests more closely with those of other shareholders.

Negatives

• The share acquisition price of $2.15 is relatively low, which could reflect a lower market valuation for BDTX at the time of the transaction.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider purchases, especially when directors opt for equity over cash, are often viewed positively by the market as they suggest management's belief in the company's long-term value. This transaction aligns with a broader trend of aligning executive and director incentives with shareholder interests through equity compensation.

Comparison to Industry Standards

• Equity compensation for non-employee directors is a common practice across the biotechnology and pharmaceutical industries, aligning director interests with shareholder value. For example, companies like Moderna (MRNA) and BioNTech (BNTX) also utilize equity-based awards as part of their director compensation structures.
• The specific value of $2.15 per share for director compensation reflects the market valuation of BDTX at the time, which can be compared to the average share prices at which directors of similar-stage biotech companies receive equity compensation, though direct comparisons require detailed compensation policy analysis.

Corporate Governance

Related Party Transactions

• The indirect beneficial ownership of 4,448,757 shares is held through New Enterprise Associates 16, L.P. (NEA 16), where the reporting person, Ali Behbahani, is a manager of NEA 16 GP, LLC, the general partner of NEA Partners 16, L.P., which in turn is the general partner of NEA 16. This represents a significant related-party holding.

Stakeholder Impact

• Shareholders: The transaction may be viewed positively as it demonstrates a director's commitment and belief in the company's value, potentially boosting investor confidence.

Key Dates

Recommendation

While the director's decision to take equity over cash is a positive signal of confidence, a single insider transaction, especially one related to compensation, is generally not sufficient to warrant a 'buy' recommendation without further fundamental analysis of the company's financial performance, strategic outlook, and market conditions. It reinforces a 'hold' position for existing investors and suggests continued monitoring for potential investors.

Keywords

Black Diamond Therapeutics, BDTX, Form 4, Insider Trading, Director Compensation, Equity Compensation, Stock Acquisition, Ali Behbahani, Beneficial Ownership